CNTO-6785
CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A) . CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) [1].
Product Specifications
UNSPSC
12352203
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Infection
Smiles
[CNTO-6785]
References & Citations
[1]Eich A, et al. A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease. COPD. 2017 Oct;14 (5) :476-483.
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P991260/
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
IL-17
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items